A new class of pain-relieving drugs, derived from histamine antagonists, has been discovered. The prototype (named improgan) shows the following characteristics after injection into the brain: A) highly effective attenuation of thermal and mechanical nociception in two rodent species, B) absence of impairment of motor function, C) independence from known opioid or histamine receptors, and D) lack of tolerance with daily dosing. The experiments below in rats and mice will reveal the mechanism of action of improgan, and evaluate the efficacy of this drug in clinically relevant pain models: (1) The improgan receptor has not yet been discovered. Radioligand binding studies with 3H-cimetidine will test the hypothesis that this ligand binds to the brain improgan receptor. Validation of this assay will lead to discovery of the improgan receptor, and to the development of new drugs acting on this receptor. (2) The effects of improgan on inflammatory and neuropathic nociceptive models will evaluate the efficacy of this drug in clinically relevant pain. (3) """"""""Off-cells"""""""" in the rostral ventromedial medulla (RVM) are crucial for RVM-mediated analgesia, and improgan appears to activate these cells. Combinations of single unit recording, microinjections, behavioral testing and iontophoresis will beperformed to reveal the neurophysiological basisfor improgan antinociception. (4) Improgan antinociception is blocked by cannabinoid CBj antagonists, yet this drug lacks affinity for the CBi receptor. In vivo studies with cannabinoid drugs and anti-sense oligonucleotides will verify mechanistic rolesfor CBi receptors and endogenous cannabinoids (endocannabinoids) in improgan antinociception. These collaborative experiments between pharmacologists, neurophysiologists and chemists will discover the mechanism of action of this novel class of agents and lead to the development of new, non-opioid pharmacotherapies for pain.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
3R01DA003816-20S1
Application #
7659801
Study Section
Special Emphasis Panel (ZRG1-IFCN-K (04))
Program Officer
Aigner, Thomas G
Project Start
1984-07-01
Project End
2010-01-31
Budget Start
2008-08-01
Budget End
2009-01-31
Support Year
20
Fiscal Year
2008
Total Cost
$38,449
Indirect Cost
Name
Albany Medical College
Department
Pharmacology
Type
Schools of Medicine
DUNS #
190592162
City
Albany
State
NY
Country
United States
Zip Code
12208
Reid, M Carrington; Ghesquiere, Angela; Kenien, Cara et al. (2017) Expanding palliative care's reach in the community via the elder service agency network. Ann Palliat Med 6:S104-S107
Reid, M Carrington; Henderson Jr, Charles R; Trachtenberg, Melissa A et al. (2017) Implementing a Pain Self-Management Protocol in Home Care: A Cluster-Randomized Pragmatic Trial. J Am Geriatr Soc 65:1667-1675
Kiosses, Dimitris N; Ravdin, Lisa D; Stern, Amy et al. (2017) Problem Adaptation Therapy for Pain (PATH-Pain): A Psychosocial Intervention for Older Adults with Chronic Pain and Negative Emotions in Primary Care. Geriatrics (Basel) 2:
Guerriero, Fabio; Bolier, Ruth; Van Cleave, Janet H et al. (2016) Pharmacological Approaches for the Management of Persistent Pain in Older Adults: What Nurses Need to Know. J Gerontol Nurs 42:49-57
Conroy, Jennie L; Nalwalk, Julia W; Phillips, James G et al. (2013) CC12, a P450/epoxygenase inhibitor, acts in the rat rostral, ventromedial medulla to attenuate morphine antinociception. Brain Res 1499:1-11
Hoerbelt, Paul; Nalwalk, Julia W; Phillips, James G et al. (2013) Antinociceptive activity of CC44, a biotinylated improgan congener. Eur J Pharmacol 714:464-71
VanAlstine, Melissa A; Hough, Lindsay B (2011) Effects of acetylenic epoxygenase inhibitors on recombinant cytochrome p450s. Drug Metab Dispos 39:1221-6
Hough, Lindsay B; Rice, Frank L (2011) H3 receptors and pain modulation: peripheral, spinal, and brain interactions. J Pharmacol Exp Ther 336:30-7
Albrecht, Phillip J; Nalwalk, Julia W; Hough, Lindsay B (2011) Efficacy of improgan, a non-opioid analgesic, in neuropathic pain. Brain Res 1424:32-7
Hough, Lindsay B; Nalwalk, Julia W; Yang, Jun et al. (2011) Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic. Pain 152:878-87

Showing the most recent 10 out of 74 publications